A decade after the first CRISPR companies burst onto the scene, the field’s central bottleneck hasn’t changed: getting the editor where it needs to go. Lipid nanoparticles and viral vectors have enabled a handful of in vivo therapies, but for most tissues, delivery remains a lethal impediment. Ingenix, a Massachusetts-based startup, thinks the answer lies in what it calls Modality Fusion—a platform that designs delivery and payload in tandem. With a $14 million Series A led by Sofinnova Partners, the company now has the capital to prove it.
The Modality Fusion Architecture
Unlike most gene editing outfits that bolt a CRISPR system onto a viral or lipid carrier, Ingenix engineers both components simultaneously. The company says its approach can tailor the delivery vehicle to the target cell type—liver, muscle, or hematopoietic stem cells—while optimizing the nuclease for on-target activity and reduced immunogenicity. The result, in theory, is a more precise edit with fewer off-target effects. For rare monogenic diseases, that could mean durable cures with a single dose, sidestepping the multi-year dosing regimens of siRNA drugs or enzyme replacement therapies.
"We don't see delivery as an afterthought—it is the therapy. Modality Fusion lets us co-design every component from day one, which is how you finally get CRISPR to work beyond the liver." — Ingenix CEO, as told to BiotechTube
Ingenix has not yet disclosed its lead indications, though the company’s job postings hint at interest in hemoglobinopathies and neuromuscular disease. That puts it in direct competition with CRISPR Therapeutics and Vertex, whose Casgevy won FDA approval for sickle cell and beta-thalassemia in 2023, and with Intellia Therapeutics, which is pushing a non-viral approach in transthyretin amyloidosis. The difference, Ingenix argues, is its ability to switch out tissue-targeting modules without reinventing the entire construct.
A Sector Under Pressure
The raise lands at a fraught moment for gene therapy. Manufacturing snafus and million-dollar price tags have chilled investor appetite, while safety signals in some AAV-based programs have regulators asking harder questions. Even the field’s biggest names are trading well below their 2021 highs. Sofinnova’s decision to back an early-stage delivery platform suggests that, despite the macro gloom, venture investors still see a gap worth filling. The firm has a history of placing bets on fundamental biology over incremental improvements—it led or co-led rounds for ocular gene therapy company GenSight and RNA editing startup Wave Life Sciences.
For now, Ingenix’s $14 million will go toward platform optimization and generating preclinical proof-of-concept data in at least two tissue types. The company expects to nominate a lead candidate by early 2027. Whether its Modality Fusion can surmount the delivery barriers that have stalled so many others is the $14 million question—and one that Sofinnova, and likely a pack of waiting crossover investors, will be watching closely.
